SDMHF News and Press, Sartorius Stedim Biotech From 01/26/23

Sartorius Stedim Biotech S.A. (SDMHF) Q4 2022 Earnings Conference Call January 26, 2023, 09:30 AM ET Company Participants Joachim Kreuzburg - CEO Rainer Lehmann - CFO, Member of Executive Board Conference Call Participants Odysseas Manesiotis - Berenberg Ma...

Sartorius Stedim Biotech S.A. ( OTCPK:SDMHF ): FY GAAP EPS of € 8.64. Revenue of € 3.49M (+21.2% Y/Y). For further details see: Sartorius Stedim Biotech S.A. GAAP EPS of €8.64, revenue of €3.49M

Sartorius Stedim Biotech press release ( OTCPK:SDMHF ): 9M GAAP EPS of €6.58. Revenue of €2.6B (+23.2% Y/Y). Sales revenue up 17.0% in constant currencies, underlying EBITDA margin at 35.0%. Outlook for 2022 specified : Sales revenue growth ...

Nine-month results 2022 of Sartorius Stedim Biotech PR Newswire Sales revenue up 17.0 percent in constant currencies, underlying EBITDA margin at 35.0 percent Overall market situation characterized by innovations and strong growth drivers; current development as ex...

Summary I'm focused on high-quality companies with growing free cash flows per share. I group my portfolio into 4 buckets: Great capital allocations, Tech Leaders, (unprofitable) High-growth and short-term trades. I want to own companies with great management so that I can sle...

Sartorius Stedim Biotech to acquire Albumedix, strengthening its portfolio of innovative advanced therapy solutions PR Newswire UK-based Albumedix Ltd. is a leader in the field of recombinant albumin-based solutions and a highly innovative and profitable company Re...

Sartorius Stedim Biotech S.A. press release ( OTCPK:SDMHF ): 1H GAAP EPS of €4.40. Revenue of €1.72B (+27.4% Y/Y). 2022 outlook confirmed: Sales revenue expected to rise by 15 to 19 percent vs. estimated growth of 9.92% Y/Y and underlying ...

Half-year results 2022 of Sartorius Stedim Biotech PR Newswire AUBAGNE, France , July 21, 2022 Sales revenue up 22.1 percent in constant currencies, underlying EBITDA margin 35.2 percent 2022 outlook confirmed: Sales revenue expected...

Sartorius AG and Sartorius Stedim are a buy after a significant drawdown. Sartorius is operating in the fast-growing biopharmaceutical industry. The company is growing rapidly and with already high profitability. Sartorius French subsidiary is the more attractive stock between...

First-quarter results 2022 of Sartorius Stedim Biotech PR Newswire Sales revenue up 27.6 percent in constant currencies, underlying EBITDA margin 35.2 percent Healthy demand situation; normalization of pandemic-related effects and development of order int...